Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Inclusion Criteria: * Histologically proven initial diagnosis of prostate adenocarcinoma * Priory treated and controlled primary tumor * Biochemical recurrence defined by prostate-specific antigen (PSA) values \>0,2 ng/ml (i.e., two consecutive increases) following radical prostatectomy + postoperative radiotherapy and a PSA value of 2 ng/ml above the nadir after high-dose RT. * Oligorecurrent disease defined as a maximum of 5 extracranial metastases in any organ, diagnosed on PSMA PET-CT or PSMA PET-MRI reported according to the E-PSMA consensus guidelines for interpretation of PSMA-PET (26). Nodal (N1) disease can be included only when accompanied by M1a-c disease, provided that the total number of spots does not exceed 5. * Serum testosterone level within normal range. * WHO performance 0-2 * Age \>= 18 years old * Absence of psychological, sociological or geographical condition potentially hampering compliance with study protocol. * Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board. * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * 2\. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs,…